Revelation Biosciences (REVB) Projected to Announce Quarterly Earnings on Thursday

Revelation Biosciences (NASDAQ:REVB) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($6.16) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Revelation Biosciences (NASDAQ:REVB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($6.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.12) by $0.03. On average, analysts expect Revelation Biosciences to post ($36.28) EPS for the current fiscal year and ($20.22) EPS for the next fiscal year.

Revelation Biosciences Stock Performance

Shares of NASDAQ REVB opened at $4.43 on Wednesday. Revelation Biosciences has a 1 year low of $3.08 and a 1 year high of $40.60. The firm has a market cap of $3.01 million, a price-to-earnings ratio of -0.05 and a beta of -0.13. The stock’s 50-day simple moving average is $5.63 and its 200-day simple moving average is $8.12.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases.

Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Revelation Biosciences is headquartered in San Diego, California, and has focused primarily on advancing its pipeline through preclinical and clinical development rather than marketing approved commercial products.